Trial Profile
Population Pharmacokinetics Analysis of AMG 416, an Allosteric Activator of the Calcium-Sensing Receptor, in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- 08 Dec 2015 New trial record